RXRX vs TEM
RXRX and TEM side by side — valuation & fundamentals (public data).
Key statistics
| Metric | RXRXRECURSION PHARMACEUTICALS, INC. | TEMTempus AI, Inc. |
|---|---|---|
| Market cap | $2.38B | $14.13M |
| P/B | — | 0.03 |
| P/S | 33.2x | 0.0x |
| Revenue | — | $1.51B(TTM) |
| Revenue growth (YoY) | 26.9% | 83.4% |
| Net income | — | -$189.27M(TTM) |
| Earnings growth (YoY) | -39.1% | 65.3% |
| EPS, diluted | — | $-1.06(TTM) |
| EBIT margin | -867.9% | -19.9% |
| ROE | -71.2% | -49.0% |
| ROIC | -181.7% | — |
| 1y total return | -27.5% | -12.0% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: RXRX frente a TEM
| Métrica | RXRX | TEM |
|---|---|---|
| Valor final | $4.1K | $19.5K |
| Retorno total | -58.6% | +95.0% |
| CAGR | -30.9% | +32.3% |
| Volatilidad | 84.4% | 97.1% |
| Sharpe | -0.08 | 0.72 |
| Sortino | -0.12 | 1.15 |
| Caída máxima | -73.9% | -59.8% |
Basado en 598 días de negociación comunes, 2024-06-14 → 2026-11-02 · tasa libre de riesgo 4.21% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)